A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate GLS-010 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Latest Information Update: 08 Sep 2023
At a glance
- Drugs Zimberelimab (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Paclitaxel
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Guangzhou Gloria Biosciences
Most Recent Events
- 06 Sep 2023 Status changed from not yet recruiting to recruiting, according to a Guangzhou Gloria Biosciences media release.
- 06 Sep 2023 According to a Guangzhou Gloria Biosciences media release, first patient dosing has been completed.
- 11 Apr 2023 New trial record